NBIX News and Press, Neurocrine Biosciences Inc. From 05/14/24

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitatio...

2024-05-13 17:41:32 ET More on Voyager Therapeutics Voyager Therapeutics: On Track To Deliver High Returns On Investment Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcr...

2024-05-13 17:00:06 ET Cory Kasimov from Evercore ISI issued a price target of $175.00 for NBIX on 2024-05-13 16:13:00. The adjusted price target was set to $175.00. At the time of the announcement, NBIX was trading at $136.15. The overall price target consensus is at $1...

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 PR Newswire CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults PR Newswire SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Pha...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults PR Newswire SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Ph...

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference PR Newswire SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pa...

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 PR Newswire CAHtalyst™ Pediatric ...

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring PR Newswire Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed 1-3 The d...

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 PR Newswire CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolesce...